Evofem Biosciences, Inc. Common Stock
EVFM
EVFM was delisted on the 10th of August, 2022.
29 hedge funds and large institutions have $22.1M invested in Evofem Biosciences, Inc. Common Stock in 2015 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 7 closing their positions.
71% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 7
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
21% more funds holding
Funds holding: 24 → 29 (+5)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
14% less capital invested
Capital invested by funds: $25.6M → $22.1M (-$3.51M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
+$3.09M |
| 2 |
CCM
Consonance Capital Management
New York
|
+$1.46M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$431K |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$321K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
+$281K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Amici Capital
New York
|
-$2.45M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$1.66M |
| 3 |
CPCM
Clifton Park Capital Management
Wilmington,
Delaware
|
-$657K |
| 4 |
PSC
Piper Sandler & Co
Minneapolis,
Minnesota
|
-$475K |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$387K |
EVFM Hedge Fund Activity: Q3 2015 in Review
29 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Evofem Biosciences, Inc. Common Stock (EVFM) for Q3 2015, worth a combined $22.1M — down 14% from $25.6M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new EVFM positions and 7 closed out — a net gain of 5 holders — while 9 added to existing stakes and 6 trimmed.
The largest buyer was UBS AM, opening a new position worth an estimated $3.09M. The largest seller was Amici Capital, cutting an estimated $2.45M.
- 29 institutional investors held Evofem Biosciences, Inc. Common Stock (EVFM) as of Q3 2015, up from 24 in Q2 2015.
- Funds reported $22.1M of Evofem Biosciences, Inc. Common Stock stock for Q3 2015, down 14% quarter-over-quarter.
- 12 funds opened new Evofem Biosciences, Inc. Common Stock positions in Q3 2015 and 7 closed out, a net change of +5 holders.
- The largest Evofem Biosciences, Inc. Common Stock buyer in Q3 2015 was UBS AM, an estimated $3.09M added.
- The largest Evofem Biosciences, Inc. Common Stock seller in Q3 2015 was Amici Capital, an estimated $2.45M sold.
Based on aggregated 13F filings for Q3 2015.